KIMS774.00

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISJUBLPHARMAINDGNONESOURCEPFIZERPOLYMEDMcap ₹30,960 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
KIMS
FY26
APOLLOHOSP
FY26
MAXHEALTH
FY26
FORTIS
FY26
Peer
Median
Valuation — at last close
P/E128.36×65.86×69.66×65.36×65.86× +95%
P/B12.10×12.82×9.36×6.70×9.36× +29%
EV/EBITDA42.56×34.95×46.08×33.84×34.95× +22%
Market Cap₹30,960 Cr₹1.28L Cr₹1.01L Cr₹68,097 Cr₹1.01L Cr -69%
Growth
Revenue CAGR 3Y21.12%14.94%22.43%13.17%14.94% +41%
Revenue CAGR 5Y24.04%19.03%27.30%17.76%19.03% +26%
Net Income CAGR 3Y-12.87%33.35%9.34%18.91%18.91% -168%
Revenue YoY (latest Q)35.33%20.56%16.70%17.46%17.46% +102%
Net Income YoY (latest Q)-56.00%38.41%4.87%2.26%4.87% -1250%
Profitability
EBITDA Margin20.54%14.94%26.79%22.84%22.84% -10%
Net Income Margin6.20%7.94%17.23%11.66%11.66% -47%
Return on Common Equity9.44%19.47%13.42%10.25%13.42% -30%
Return on Capital Employed7.96%18.41%11.94%11.81%11.94% -33%
Return on Assets3.12%9.02%8.37%6.67%8.37% -63%
Credit & Quality
Total Debt/Equity1.27×0.57×0.32×0.28×0.32× +297%
Interest Coverage2.56×6.44×7.64×5.20×6.44× -60%
Scale — latest FY
Revenue / Total Income₹3,905 Cr₹25,229 Cr₹8,373 Cr₹9,128 Cr₹9,128 Cr -57%
Net Income₹242 Cr₹2,003 Cr₹1,442 Cr₹1,064 Cr₹1,442 Cr -83%
Total Assets₹7,759 Cr₹22,197 Cr₹17,231 Cr₹15,966 Cr₹17,231 Cr -55%
EPS₹6.03₹135.04₹14.83₹13.8₹14.83 -59%
Book Value per Share₹63.96₹693.64₹110.43₹134.69₹134.69 -53%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.